Motley Fool  Jul 20  Comment 
Regeneron Pharmaceuticals is packed with potential, and it's on sale -- so this Fool decided to take advantage.
Motley Fool  Jul 13  Comment 
Continuing concerns over Praluent weigh on Regeneron, but shareholders would be wise to look at the whole picture.
Motley Fool  Jul 12  Comment 
Amgen has won FDA approval for a new device that allows for monthly dosing of its cholesterol-busting drug Repatha. Is it a game-changing innovation in its fight against Regeneron Pharmaceuticals and Sanofi?
newratings.com  Jul 5  Comment 
PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said that the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Praluent (alirocumab) for the treatment of uncontrolled...
Motley Fool  Jul 1  Comment 
Positive clinical news is being overshadowed by an unfavorable court ruling and slowing growth of its core business.
Benzinga  Jun 29  Comment 
Bernstein has initiated coverage of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) with an Outperform rating and $400 price target, citing a "good entry point for one of stronger growers in biotech." "Regeneron is a growth-phase biopharma with one...
Benzinga  Jun 23  Comment 
Citi’s Robyn Karnauskas mentioned three key takeaways after meeting with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) management - CEO Leonard Schleifer, CFO Bob Landry and Director IR Manisha Narasimhan. These were: Injunction decision...
Forbes  Jun 22  Comment 
Looking at the sectors faring best as of midday Wednesday, shares of Healthcare companies are outperforming other sectors, higher by 0.8%. Within that group, Celgene Corp. (NASD: CELG) and Regeneron Pharmaceuticals, Inc. (NASD: REGN) are two large...
Forbes  Jun 21  Comment 
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...


Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki